Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
Braz. j. infect. dis
;
13(5): 353-355, Oct. 2009. tab
Artigo
em Inglês
| LILACS
| ID: lil-544988
ABSTRACT
Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. So far, no study has been performed in Latin America to evaluate the clinical implication of this finding. Here we studied the potential for galactomannan detection in piperacillin-tazobactam batches commercialized in the Brazilian market. Five batches from distinct laboratories were tested in duplicate in the Platelia Aspergillus EIA according to the manufacturer's instructions. Only one drug showed crossreaction at a cut-off of 0.5. Human serum was spiked with this particular drug aiming to mimic achievable piperacillin-tazobactam concentrations in the serum. Results were all negative for galactomannan detection, even at high drug concentrations. Results from this pilot study suggest that piperacillin-tazobactam might not be a clinically significant cause of false-positive results in the Platelia Aspergillus EIA test in Brazil.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Aspergillus
/
Técnicas Imunoenzimáticas
/
Mananas
/
Antibacterianos
Tipo de estudo:
Estudo diagnóstico
/
Estudos de avaliação
País/Região como assunto:
América do Sul
/
Brasil
Idioma:
Inglês
Revista:
Braz. j. infect. dis
Assunto da revista:
Doenças Transmissíveis
Ano de publicação:
2009
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Brazilian government/BR
/
Santa Casa Complexo Hospitalar/BR
/
Universidade Federal do Rio Grande do Sul/BR
Similares
MEDLINE
...
LILACS
LIS